To treat NAFLD/NASH, several drugs have been shown to be beneficial in animal models [6,7], and novel activators for peroxisome proliferator-activated receptor (PPAR) (elafibranor) and farnesoid X receptor (FXR) (obeticholic acid) are currently under phase 3 studies in human cohorts with promising results [4]. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.